|
|
-Review-
Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis
Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan
Reflux esophagitis is characterized by excessive esophageal acid exposure. To treat reflux esophagitis, it is necessary to reduce excessive esophageal acid exposure to within the normal range. The first-line drug for the treatment of reflux esophagitis is a standard-dose proton-pump inhibitor (PPI), which is also recommended by the Evidence-based Clinical Practice Guidelines 2015 for gastroesophageal disease of the Japanese Society of Gastroenterology. It has been reported that the response to a standard dose of PPI in patients with mild reflux esophagitis is 90-100%, and that in patients with severe reflux esophagitis is 80-85%. However, PPI-resistant reflux esophagitis has been increasing. When the standard dose of PPI is not effective, modification of the lifestyle with PPI therapy, switching to another PPI, or a change in the administration method (before meals), as well as double-dose PPI (in divided doses), may be effective. In addition, vonoprazan (potassium-competitive acid blocker), which has rapid and potent acid-suppressive effects, became available in February 2015 in Japan. In the clinical trial data, vonoprazan is very effective for reflux esophagitis. However, clinical data on vonoprazan are still insufficient. The establishment of a new treatment for reflux esophagitis taking advantage of the rapid and potent acid-suppressive effects is awaited.
J Nippon Med Sch 2017; 84: 209-214
Keywords
reflux esophagitis, proton-pump inhibitor (PPI), PPI-refractory reflux esophagitis, esophageal motility, potassium-competitive acid blocker (P-CAB)
Correspondence to
Katsuhiko Iwakiri, MD, PhD, Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
k-iwa@nms.ac.jp
Received, May 30, 2017
Accepted, August 8, 2017
PDF (133K)